EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of a First‐in‐Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity

Zihan Qu, Frederick Nguele Meke, Zheng Zhang, Aaron D Krabill, Christine S Muli, Brenson A Jassim, Jiajun Dong, Quyen D Nguyen, Yunpeng Bai, Jinyue Li, Yiming Miao, Bardia Asadi und 5 weitere

Angewandte Chemie International Edition · 2026

DOI: 10.1002/anie.202525126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Zihan Qu und 16 weiteren Autor:innen. Beteiligte Einrichtung: James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana, 47907, USA. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 6, Enzyme Inhibitors, Immunotherapy, Drug Discovery. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIA NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Src homology 2 domain‐containing phosphatase 1 (SHP1), encoded by PTPN6 , is a key intracellular mediator of inhibitory immune signals. SHP1 is garnering attention as a potential immunotherapeutic target since SHP1 deletion elicits strong antitumor activity by boosting both innate and adaptive immunity. Unfortunately, no quality SHP1 inhibitor exists to demonstrate its translatability owing to the challenges posed by the chemistry of the phosphatase active site. Herein, we describe the discovery of a first‐in‐class, phenyl chloroacetamide‐based covalent allosteric SHP1 inhibitor M029 through covalent fragment screening and multiparameter optimization. M029 inactivates SHP1 by covalently binding to a non‐conserved and cryptic Cys480 far away from the active site, thus uncovering a novel allosteric mechanism for SHP1 inhibition. In addition, M029 is highly selective for SHP1 and exhibits robust cellular target engagement. Importantly, M029 is orally active and blocks tumor progression in a syngeneic cancer model by activating natural killer cells and cytotoxic CD8 + T cells, along with reduced T cell exhaustion. Together, this study reveals a ligandable Cys that can be exploited for allosteric inhibition of SHP1, which has been refractory to targeted pharmacologic manipulation. The work also demonstrates small‐molecule SHP1 inhibition as a compelling approach for new cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Tyrosine Phosphatase, Non-Receptor Type 6Enzyme InhibitorsImmunotherapyDrug DiscoveryHumansAnimalsAllosteric RegulationMiceAcetamidesMolecular StructureStructure-Activity Relationship

Stichwörter der Autor:innen

Allosteric inhibitionCovalent inhibitorsImmunotherapyLigandable cysteineProtein tyrosine phosphatases

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 6Enzyme InhibitorsPTPN6 protein, humanAcetamides

Autor:innen und Institutionen

  • James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana, 47907, USA.
  • Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA.
  • Department of Biochemistry, Purdue University, 175 South University Street, West Lafayette, Indiana, 47907, USA.
  • Institute for Cancer Research, Purdue University, 201 South University Street, West Lafayette, Indiana, 47907, USA.
  • Institute for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, Indiana, 47907, USA.

ORCID-Profile: Zhong-Yin Zhang

Förderung

  • NIH HHS
  • NIA NIH HHS
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Qu, Z., Meke, F. N., Zhang, Z., Krabill, A. D., Muli, C. S., Jassim, B. A., Dong, J., Nguyen, Q. D., Bai, Y., Li, J., Miao, Y., Asadi, B., Johnson, L. M., Miao, J., Trader, D. J., Tao, W. A., & Zhang, Z. Y. (2026). Discovery of a First‐in‐Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202525126

Vancouver

Qu Z, Meke FN, Zhang Z, Krabill AD, Muli CS, Jassim BA, et al. Discovery of a First‐in‐Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.202525126

BibTeX
@article{Qu2026,
  author = {Qu, Zihan and Meke, Frederick Nguele and Zhang, Zheng and Krabill, Aaron D and Muli, Christine S and Jassim, Brenson A and Dong, Jiajun and Nguyen, Quyen D and Bai, Yunpeng and Li, Jinyue and Miao, Yiming and Asadi, Bardia and Johnson, Levi M and Miao, Jinmin and Trader, Darci J and Tao, W Andy and Zhang, Zhong-Yin},
  title = {Discovery of a First‐in‐Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity},
  journal = {Angewandte Chemie International Edition},
  year = {2026},
  doi = {10.1002/anie.202525126}
}
Kostenlos starten →